VALERIE GLASS: Open Payments
NPI 1780369140 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$753 in 44 payments from 13 companies in 2025. Trend: 2023 $350 · 2024 $1,200 · 2025 $753
Food & beverage: $753
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $382 |
| Aimmune Therapeutics, Inc. | 3 | $62 |
| Madrigal Pharmaceuticals | 1 | $47 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Novo Nordisk Inc | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| EVOKE PHARMA, INC. | 1 | $20 |
| Gilead Sciences, Inc. | 1 | $19 |
| Exact Sciences Corporation | 1 | $19 |
Products named: RINVOQ, LINZESS, CREON, SKYRIZI, ZENPEP, REZDIFFRA, VOQUEZNA, ENTYVIO.
Industry payments across AL — which companies pay providers there.
